Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $122.88, giving the company a market capitalization of 152.13B. It carries a P/E multiple of 18.30 and pays a dividend yield of 2.7%.
During the trading session on 2025-11-11, Gilead Sciences(GILD) shares reached a daily high of $122.89 and a low of $118.58. At a current price of $122.88, the stock is +3.6% higher than the low and still -0.0% under the high.
Trading activity shows a volume of 6.28M, compared to an average daily volume of 7.66M.
The stock's 52-week range extends from a low of $86.08 to a high of $124.61.
The stock's 52-week range extends from a low of $86.08 to a high of $124.61.
GILD News
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Shareholder Yield...
(RTTNews) - Gilead Sciences, Inc. (GILD) on Friday reported that the Phase 3 ASCENT-07 study, evaluating Trodelvy versus chemotherapy as a first-line treatment...
Gilead (GILD) Sciences announced the Phase 3 ASCENT-07 study investigating Trodelvy versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/...
Analyst ratings
70%
of 30 ratingsMore GILD News
Gilead (GILD) announced new long-term data reinforcing the safety and efficacy profile of Livdelzi for people living with primary biliary cholangitis. Findings...
Gilead Sciences recently reported strong third-quarter earnings with revenue of US$7.77 billion and net income of US$3.05 billion, raised its 2025 earnings guid...
Maxim Group analyst Michael Okunewitch has maintained their neutral stance on GILD stock, giving a Hold rating on October 31. Elevate Your Investing Strategy: T...
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affe...
Gilead Sciences (GILD) released its third-quarter results showing year-over-year gains in both revenue and net income. The company also raised its full-year ear...